Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: infliximab

Trying to Parse True Meaning of Pain Can be Challenging for Rheumatologists

Trying to Parse True Meaning of Pain Can Be Challenging for Rheumatologists

Simon M. Helfgott, MD  |  March 15, 2016

Discussing aching joints, sore muscles and tender limbs is all in our day’s work. We are rheumatologists; we deal in misery. But trying to parse the true meaning of these terms is among the most vexing of clinical challenges.

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:DiagnosisPainpatient carerheumatologistrheumatologyswelling

Diagnosis Can Be Elusive for Fever of Unknown Origin

Diagnosis Can Be Elusive for Fever of Unknown Origin

Charles Radis, DO  |  March 15, 2016

Settling into room 501 at Maine Medical Center, Mrs. N was on her way to the bathroom when she felt it coming on. One moment she was okay; the next, her chest felt damp and cold, even as her face flushed and her temperature spiked. Her forehead glistened beads of warm sweat. She felt the…

Filed under:Conditions Tagged with:Diagnosisfeverpatient careprodromeRheumatic DiseaseRheumatoid arthritisrheumatologistSarcoidosis

2015 ACR/ARHP Annual Meeting: Unknowns Persist Around Sarcoidosis Etiology, Pathogenesis, Treatment

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—The Kveim-Siltzbach skin test for a diagnosis of sarcoidosis was developed in 1941, then popularized in 1961. Since then, the knowledge base about the disease has not expanded much, said Kristin Highland, MD, who has dual appointments at Cleveland Clinic’s Respiratory Institute and Orthopedics and Rheumatology Institute. “We don’t know a whole lot more…

Filed under:ConditionsMeeting ReportsOther Rheumatic Conditions Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)DiagnosisEtiologyinflammatoryPathogenesisrheumatologistSarcoidosisTreatment

2015 ACR/ARHP Annual Meeting: Skin Issues in Rheumatic Diseases Present Challenges

Thomas R. Collins  |  March 15, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMeeting ReportsMyositisResearch RheumSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingAmerican College of Rheumatology (ACR)dermatitisDermatologydermatomyositisDiagnosisImmunologyLupusResearchRheumatic DiseaseskinSLEsubacute cutaneous lupus erythematosus

The ACR Addresses the FDA about the Safe Adoption of Biosimilars in the U.S.; Plus Tofacitinib Approved for RA & Romosozumab May Reduce Fracture Risk

Michele B. Kaufman, PharmD, BCGP  |  March 9, 2016

The ACR has continued its advocacy to ensure the safe adoption of biosimilars in the U.S., most recently addressing an FDA public hearing. Also, the FDA has approved tofacitinib for RA, and a clinical trial of romosozumab for patients with osteoporosis met its primary endpoint…

Filed under:Biologics/DMARDsDrug Updates Tagged with:American College of Rheumatology (ACR)BiosimilarsFDAFood and Drug AdministrationinfliximabromosozumabTofacitinibtofacitinib citrate

The Biosimilars Debate Heats Up: Potential cost savings weighed against patient health & safety

Susan Bernstein  |  March 1, 2016

After years of speculation about potential cost savings and debates on safety, biosimilars are about to step onto the stage of rheumatic disease treatment. On Feb. 9, the Arthritis Advisory Committee of the U.S. Food and Drug Administration (FDA) met in Washington, D.C., and recommended the approval of CT-P13, a proposed biosimilar to infliximab (Remicade),…

Filed under:Biologics/DMARDsDrug Updates Tagged with:American College of Rheumatology (ACR)BiosimilarscostsFDAFood and Drug Administrationinfliximab

Dermatology & Immunology: Skin Issues Can Present Challenges

Thomas R. Collins  |  February 23, 2016

SAN FRANCISCO—A 40-year-old woman shows up in the clinic with scarring alopecia, with an area of hyperpigmentation on the rim of her scalp, extending from just behind the temple to behind her ears. An examination with a dermatoscope shows hyperkeratotic follicular plugging. The case—in this example, the discoid form of cutaneous lupus erythematosus (DLE)—is one…

Filed under:ConditionsMyositisSystemic Lupus Erythematosus Tagged with:2015 ACR/ARHP Annual MeetingDermatologydermatomyositisImmunologyLupusskin

FDA Advisory Panel Strongly Backs Biosimilar Form of Remicade

Reuters Staff  |  February 6, 2016

(Reuters)—A medical advisory panel to the U.S. Food and Drug Administration on Tuesday recommended approval of a cheaper biosimilar form of Johnson & Johnson’s arthritis drug Remicade (infliximab) that could eventually batter sales of the branded product. The panel, by a vote of 21-3, supported use of the biosimilar from Celltrion Inc. and Pfizer Inc.,…

Filed under:Axial SpondyloarthritisBiologics/DMARDsDrug Updates Tagged with:Ankylosing SpondylitisCelltrion Inc.FDAFood and Drug Administrationinfliximabmonoclonal antibodyRemsimaRheumatoid Arthritis (RA)

Newer Biologics for RA on Par with TNF-Inhibitors for CV Risk

Laura Newman  |  February 2, 2016

NEW YORK (Reuters Health)—The newer disease-modifying drugs for rheumatoid arthritis appear to offer the same or even better cardiovascular (CV) protection than older tumor necrosis factor (TNF) inhibitors, hints a large study. “We really haven’t had a good understanding on where the non-TNF biologics and CV risk stand,” Dr. Jeffrey R. Curtis of the University…

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:cardiovascularDisease-modifying antirheumatic drugs (DMARDs)Myocardial infarctionnon-TNF biologicsRheumatoid Arthritis (RA)TNFtumor necrosis factor

3 Clinical Trials Examine Sirukumab for RA; Plus TNF-α Combination & Monotherapies Are Compared for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  January 27, 2016

Three clinical trials are evaluating subcutaneous sirukumab for safety and efficacy in treating rheumatoid arthritis. And a study found no significant difference in persistence and remission for TNF-α monotherapy when compared with TNF-α plus conventional DMARD combination therapy for treating psoriatic arthritis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesPsoriatic Arthritis Tagged with:combination therapyDisease-modifying antirheumatic drugs (DMARDs)Psoriatic ArthritisRheumatoid Arthritis (RA)sirukumabTNF inbhibitor

  • « Previous Page
  • 1
  • …
  • 24
  • 25
  • 26
  • 27
  • 28
  • …
  • 41
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences